Chen, Yunching
Liu, Ya-Chi
Sung, Yun-Chieh
Ramjiawan, Rakesh R.
Lin, Ts-Ting
Chang, Chih-Chun
Jeng, Kuo-Shyang
Chang, Chiung-Fang
Liu, Chun-Hung
Gao, Dong-Yu
Hsu, Fu-Fei
Duyverman, Annique M.
Kitahara, Shuji
Huang, Peigen
Dima, Simona
Popescu, Irinel
Flaherty, Keith T.
Zhu, Andrew X.
Bardeesy, Nabeel
Jain, Rakesh K.
Benes, Cyril H.
Duda, Dan G.
Article History
Received: 15 July 2016
Accepted: 6 February 2017
First Online: 9 March 2017
Competing interests
: R.K.J. received consultant fees from Ophthotech, Puretech, SynDevRx, and XTuit. R.K.J. owns equity in Enlight, Ophthotech, SynDevRx, and XTuit and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund. D.G.D. received research grants from Merrimack, Leap, Bristol-Meyers-Squibb and Bayer. No reagents or funding from these companies were used in these studies. There is no significant financial or other competing interest in the work. All remaining authors have no potential conflicts to report.